Loading…

Chidamide-BEAC plus autologous stem cell transplantation in high-risk non-Hodgkin lymphoma: a phase II clinical trial

Chidamide, a novel subtype-selective histone deacetylase inhibitor (HDACi), can directly inhibit tumor cell cycle progression, induce tumor cell apoptosis, and restore the sensitivity of drug-resistant tumor cells to drugs by loosening chromatin and exposing deoxyribonucleic acid (DNA). The protocol...

Full description

Saved in:
Bibliographic Details
Published in:Chinese medical journal 2023-06, Vol.136 (12), p.1491-1493
Main Authors: Xia, Yi, Wang, Li, Ding, Kaiyang, Wu, Jiazhu, Yin, Hua, Hu, Maogui, Shen, Haorui, Liang, Jinhua, Chen, Ruize, Li, Yue, Zhu, Huayuan, Li, Jianyong, Xu, Wei
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chidamide, a novel subtype-selective histone deacetylase inhibitor (HDACi), can directly inhibit tumor cell cycle progression, induce tumor cell apoptosis, and restore the sensitivity of drug-resistant tumor cells to drugs by loosening chromatin and exposing deoxyribonucleic acid (DNA). The protocol of this study was approved by the Institutional Review Board of Jiangsu Province Hospital and Anhui Provincial Cancer Hospital (No. 2017-SR-271). [...]63 patients were included in the per-protocol set (PPS) [Supplementary Figure 1, http://links.lww.com/CM9/B617]. [...]chidamide with anti-programmed cell death protein 1 achieved an objective response rate of 58.3% and a CR rate of 44.4% in treating advanced and relapsed/refractory ENKTL.
ISSN:0366-6999
2542-5641
DOI:10.1097/CM9.0000000000002636